Everyone should have the opportunity to lead a healthy life. This requires that we advance equitable access to healthcare and address some of the world’s most devastating and neglected diseases.
We are proud that Johnson & Johnson’s actions to expand access to our medicines and focus on addressing diseases that disproportionately impact people in lower- and middle-income countries has made us the 2nd-ranked company globally in the 2022 Access to Medicine Index.
Our industry-leading performance marks an improvement, up from 3rd in 2021, and is the sixth consecutive time we are featured as a top three performer by the Index. This is made possible thanks to an enduring commitment and a focus on providing patients around the world access to our lifesaving medicines.
Our high rank is an important validation of our decades-long, deliberate, and focused strategy and a testament to our colleagues and partners around the world who work every day to enable access to our innovative medicines and technologies in almost 100 lower- and middle-income countries.
We apply access & pricing principles across our entire pharmaceutical portfolio, planning for access early in the research phase. While our dedicated global public health team applies a lab-to-last-mile approach to fight diseases like tuberculosis, HIV, Ebola, and intestinal worms: innovating across all that we do to develop and deliver much-needed medicines, strengthening health systems and supporting frontline health workers.
Recognizing much more needs to be done we will continue to build on our approach to meet the needs of people today and the challenges the world faces tomorrow.
*** ***
The Access to Medicine Index is a biennial report card that grades the world’s largest pharmaceutical companies on their efforts to advance access to medicines to lower- and middle-income countries. Since the previous ATMI was published, Johnson & Johnson is recognized for several major accomplishments, including:
· Donating more than 2 billion doses since 2006 of our medicine to treat children infected with intestinal worms;
· Delivering more than 550,000 courses to date of our medicine to treat multidrug-resistant tuberculosis (MDR-TB);
· Launching numerous initiatives to help find the “missing millions” of people with undiagnosed tuberculosis;
· Launched three Centers for Global Health Discovery, a network of research partnerships around the world that are tackling entrenched and emerging health challenges, including TB, antimicrobial resistance (AMR) and dengue
· Completing a Phase 1 clinical study evaluating a dengue-specific antiviral for treatment and prophylactic use;
· Receiving World Health Organization Prequalification of our Ebola vaccine regimen and supporting the vaccination of more than 300,000 people who live under the constant threat of an Ebola outbreak
· Investing $100 million to help establish the $1 billion Antimicrobial Resistance (AMR) Action Fund, which aims to bring two-to-four new antibiotics to patients by 2030; and
· Committing $15 million, via the Johnson & Johnson Foundation, to the Africa Frontline First Catalytic Fund to help build an institutionalized work force of 200,000 community health workers in up to 10 African countries.
In addition, we’re proud to invest in a diverse group of initiatives aimed at improving supply chains and manufacturing, building R&D capacity and strengthening health systems, all of which were recognized by the ATMI and are critical to advance equitable access to healthcare.